Diversified Trust Co Boosts Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Diversified Trust Co raised its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 2.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 26,649 shares of the medical research company’s stock after buying an additional 620 shares during the quarter. Diversified Trust Co’s holdings in Edwards Lifesciences were worth $1,759,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Crewe Advisors LLC purchased a new stake in shares of Edwards Lifesciences during the first quarter valued at approximately $28,000. First Community Trust NA bought a new position in Edwards Lifesciences in the 2nd quarter valued at approximately $29,000. Riverview Trust Co purchased a new stake in Edwards Lifesciences during the 1st quarter valued at $34,000. Webster Bank N. A. purchased a new stake in Edwards Lifesciences during the 2nd quarter valued at $39,000. Finally, Rise Advisors LLC raised its stake in shares of Edwards Lifesciences by 125.0% in the first quarter. Rise Advisors LLC now owns 477 shares of the medical research company’s stock worth $46,000 after purchasing an additional 265 shares during the last quarter. 79.46% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently commented on EW. Deutsche Bank Aktiengesellschaft dropped their price objective on Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating on the stock in a research report on Thursday, July 25th. Jefferies Financial Group lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and reduced their price target for the stock from $85.00 to $70.00 in a research note on Wednesday, September 18th. Robert W. Baird downgraded shares of Edwards Lifesciences from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $102.00 to $70.00 in a research report on Thursday, July 25th. The Goldman Sachs Group cut their target price on shares of Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating for the company in a research report on Friday, July 26th. Finally, Bank of America cut Edwards Lifesciences from a “buy” rating to a “neutral” rating and lowered their price target for the company from $105.00 to $75.00 in a report on Thursday, July 25th. Sixteen investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $77.27.

Edwards Lifesciences Stock Up 6.2 %

EW opened at $68.55 on Wednesday. The company has a market capitalization of $41.31 billion, a PE ratio of 29.55, a price-to-earnings-growth ratio of 2.80 and a beta of 1.13. The firm has a 50-day simple moving average of $66.66 and a two-hundred day simple moving average of $80.70. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The business had revenue of $1.63 billion during the quarter, compared to analysts’ expectations of $1.65 billion. During the same quarter last year, the business posted $0.66 EPS. The firm’s revenue for the quarter was up 6.7% compared to the same quarter last year. Analysts forecast that Edwards Lifesciences Co. will post 2.71 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the transaction, the vice president now owns 29,333 shares in the company, valued at $2,051,843.35. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $66.77, for a total transaction of $333,850.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,133,916.72. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the transaction, the vice president now directly owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 11,250 shares of company stock worth $751,688. Insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.